Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. StockHK
  3. 01093
All Hong Kong stocks quotes are at least 15 minutes delayed.
01093 logo
01093
CSPC PHARMA
HKD
9.710
0.090
(0.94%)
1D
AI Analysis for 01093
AI Analysis
High
9.330
Open
8.230
VWAP
8.98
Vol
193.00M
Mkt Cap
120.75B
Low
8.100
Amount
1.73B
EV/EBITDA(TTM)
20.93
Total Shares
11.52B
EV
12.70B
EV/OCF(TTM)
--
P/S(TTM)
3.65
CSPC Pharmaceutical Group Ltd is an investment holding company primarily engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through three segments. The Finished Drugs segment in engaged in the research and development, manufacture and sale of pharmaceutical products and licensing business. The Bulk Products segment is engaged in the manufacture and sale of vitamin C, and antibiotic products in bulk powder form. The Functional Food and Others segment is engaged in the manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. The Company’s product therapeutic areas include nervous system, oncology, anti-infectives, cardiovascular, respiratory system, digestion and metabolism and others. The Company conducts its business in the domestic and overseas markets.
Show More

News

aastocks
4.5
03-12aastocks
<Daily Summary> HSI Ends at 25,716, Dropping 182 Points; HSTI Finishes at 5,027, Down 27 Points; CSPC PHARMA Falls by More than 4%; CNOOC, CHINA SHENHUA, CHINA RISUN GP, QINGSONG HEALTH, and 160 HEALTH Reach New Peaks; Market Trading Volume Increases
  • Market Performance: The Hang Seng Index (HSI) fell by 182 points (0.7%) to close at 25,716, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.

  • Active Heavyweights: Major stocks like Alibaba, Tencent, and Meituan saw slight declines, with Alibaba closing at $131.6 (-1.2%) and Tencent at $546.5 (-1%).

  • Notable Movers: Xpeng and JD Logistics were among the gainers, with Xpeng rising 4.4% to $78.45, while CSPC Pharma and Nongfu Spring faced significant losses, dropping 4.5% and 4.4%, respectively.

  • Short Selling Trends: High short selling ratios were observed in several stocks, including Meituan (46.5%) and Nongfu Spring (53.8%), indicating increased bearish sentiment among investors.

aastocks
4.5
03-12aastocks
<Midday Update> HSI Falls 318 Points; HSTI Declines by 60 Points; CMOC Drops Over 5%; CNOOC, CHINA SHENHUA, CHINA RISUN GP, QINGSONG HEALTH, YANKUANG ENERGY Reach New Peaks
  • Market Performance: The Hang Seng Index (HSI) fell by 318 points (1.2%) to 25,579, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.

  • Active Heavyweights: Major stocks like Alibaba, Meituan, and Tencent saw significant drops, with Alibaba closing down 2.3% and Tencent down 1.1%, amidst high short selling activity.

  • Notable Movers: CMOC and Nongfu Spring were among the biggest losers, dropping over 5%, while China Risun GP and Qingsong Health achieved notable gains, with China Risun GP up 18.3%.

  • Short Selling Trends: The report highlighted substantial short selling across various stocks, indicating bearish sentiment in the market, particularly for companies like Meituan and Techtronic Industries.

aastocks
4.5
03-06aastocks
<Midday Update> HSI Rises by 468 Points; HSTI Gains 177 Points; XIAOMI Surges Over 5%; BABA Increases Over 4%; TENCENT Climbs Over 3%
  • Market Performance: The Hang Seng Index (HSI) rose by 468 points (1.9%) to 25,789, while the Hang Seng Tech Index (HSTI) increased by 177 points (3.7%) to 4,973, and the Hang Seng China Enterprises Index (HSCEI) gained 187 points (2.2%) to 8,638.

  • Top Gainers: Notable stock performances included JD Logistics, which surged 21.3%, JD up 8.5%, and Trip.com rising 7.0%. Major companies like Xiaomi, Alibaba, and Tencent also saw significant increases in their stock prices.

  • Short Selling Activity: High short selling volumes were reported for several stocks, with Alibaba and JD having short selling ratios of 16.072% and 50.972%, respectively, indicating investor caution despite their price increases.

  • Other Notable Movements: Stocks like TransThera and Bayzed Health experienced substantial gains of 34.9% and 21.5%, respectively, while Chinahongqiao saw a decline of 3.3%, reflecting varied performance across different sectors.

aastocks
4.5
03-03aastocks
<Daily Summary> HSI Falls by 291 Points; HSTI Declines by 112 Points; XIAOMI Drops More Than 4%; PETROCHINA, CNOOC, OOIL, UNITEDENERGY GP, and COSCO SHIP HOLD Reach New Peaks; Market Turnover Increases
  • Market Performance: The Hang Seng Index (HSI) fell by 291 points (1.1%) to close at 25,768, with a total market turnover of $370.55 billion.

  • Active Heavyweights: Major stocks like Xiaomi, Meituan, and Alibaba experienced declines, with Xiaomi dropping 4.7% and Meituan down 2.3%.

  • Notable Movers: Xinyi Solar and Zijin Mining saw significant losses, with Xinyi Solar down 6.3% and Zijin Mining down 6.1%, while ENN Energy and PetroChina gained 5.1% and 5%, respectively.

  • Short Selling Trends: High short selling ratios were observed in several stocks, including Ping An at 27% and BYD Electronic at 28.6%, indicating increased bearish sentiment among investors.

aastocks
4.5
03-03aastocks
<Midday Update> HSI Ends Midday at 25,985, Decreasing by 74 Points; HSTI at 4,938, Down 50 Points; XIAOMI Falls Over 3%; PETROCHINA, OOIL, CNOOC, UNITEDENERGY GP, and COSCO SHIP ENGY Reach New Peaks
  • Market Performance: The Hang Seng Index (HSI) fell by 74 points (0.3%) to 25,985, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.

  • Active Heavyweights: Notable stock movements included Xiaomi and Meituan, which saw declines of 3% and 1.2% respectively, while Tencent and Alibaba experienced slight gains.

  • Significant Declines: Xinyi Solar, Pop Mart, and XPeng faced substantial drops, with declines of 5.4%, 4.7%, and 4.6% respectively, indicating a challenging day for these companies.

  • Top Gainers: Companies like PetroChina and CNOOC saw positive movements, with PetroChina rising 4% to a new high, while other stocks like Hao Tian International and Zhongyu Energy experienced significant increases.

Money Flow
Over the past 66 trading days, overall net money flow is -265.91M, with retail investors contributing -123.16M and major investors adding -48.01M.
Net Buy $ Volume
Net Sell $ Volume
Jefferies
downgrade
$8
2026-03-27
Reason
BofA Securities downgraded CSPC Pharmaceutical's rating to 'Underperform' due to a projected decline in revenue and net profit for 2025, alongside downward revisions in earnings per share forecasts for the following years.
Jefferies
Price Target
$8
2026-03-27
downgrade
BofA Securities downgraded CSPC Pharmaceutical's rating to 'Underperform' due to a projected decline in revenue and net profit for 2025, alongside downward revisions in earnings per share forecasts for the following years.
China Merchants Securities (HK)
China Merchants Securities (HK)
Buy
downgrade
2026-03-27
Reason
China Merchants Securities (HK) has lowered its target price for CSPC Pharmaceutical Group due to an expected 10.4% decline in total revenue in 2025, primarily driven by volume-based procurement and prescription control. Despite this, the firm maintains a 'Buy' rating as it anticipates stabilization in core domestic sales by 2026 and sees potential for long-term growth through external licensing deals and a differentiated product pipeline.
China Merchants Securities (HK)
Buy
Price Target
2026-03-27
downgrade
China Merchants Securities (HK) has lowered its target price for CSPC Pharmaceutical Group due to an expected 10.4% decline in total revenue in 2025, primarily driven by volume-based procurement and prescription control. Despite this, the firm maintains a 'Buy' rating as it anticipates stabilization in core domestic sales by 2026 and sees potential for long-term growth through external licensing deals and a differentiated product pipeline.
Jefferies
Underperform
maintain
2026-03-26
Reason
Jefferies maintains an 'Underperform' rating for CSPC Pharmaceutical Group due to concerns over declining annual revenue and potential risks from Volume-Based Procurement (VBP), despite management's expectations for growth in the finished drug business. The firm believes that adverse VBP factors will continue to impact performance this year, and the increasing expectations in the market raise the risk of disappointment.
Jefferies
Underperform
Price Target
2026-03-26
maintain
Jefferies maintains an 'Underperform' rating for CSPC Pharmaceutical Group due to concerns over declining annual revenue and potential risks from Volume-Based Procurement (VBP), despite management's expectations for growth in the finished drug business. The firm believes that adverse VBP factors will continue to impact performance this year, and the increasing expectations in the market raise the risk of disappointment.
Citi
Buy
downgrade
2026-03-26
Reason
Citi's analyst rating for CSPC Pharmaceutical Group is based on the company's recent financial performance, which showed a 10% decrease in both revenue and net profit year-on-year. Despite a reduction in sales expenses and an increase in R&D costs, the management maintains a conservative outlook, expecting positive results by fiscal year 2026. The firm has revised down revenue and EPS forecasts for the next two years but still maintains a 'Buy' rating, reflecting confidence in future business expansion collaborations and potential product approvals.
Citi
Buy
Price Target
2026-03-26
downgrade
Citi's analyst rating for CSPC Pharmaceutical Group is based on the company's recent financial performance, which showed a 10% decrease in both revenue and net profit year-on-year. Despite a reduction in sales expenses and an increase in R&D costs, the management maintains a conservative outlook, expecting positive results by fiscal year 2026. The firm has revised down revenue and EPS forecasts for the next two years but still maintains a 'Buy' rating, reflecting confidence in future business expansion collaborations and potential product approvals.
Nomura
Buy
maintain
2026-02-16
Reason
The analyst rating for CSPC PHARMA was maintained at "Buy" by Nomura due to several positive factors. The firm expects a 20% year-over-year revenue growth in 4Q25, slightly surpassing market consensus. Additionally, the anticipated increase in collaboration revenue and a higher gross profit margin contributed to the positive outlook. Nomura also raised its revenue and earnings forecasts for FY2025 and FY2026, which further supported the decision to elevate the target price from $9.11 to $12.04.
Nomura
Buy
Price Target
2026-02-16
maintain
The analyst rating for CSPC PHARMA was maintained at "Buy" by Nomura due to several positive factors. The firm expects a 20% year-over-year revenue growth in 4Q25, slightly surpassing market consensus. Additionally, the anticipated increase in collaboration revenue and a higher gross profit margin contributed to the positive outlook. Nomura also raised its revenue and earnings forecasts for FY2025 and FY2026, which further supported the decision to elevate the target price from $9.11 to $12.04.
CICC
CICC
Outperform
maintain
$11 -> $12
2026-02-02
Reason
The analyst rating for CSPC Pharma (01093.HK) is maintained at "Underperform" by BofAS due to sales pressure, despite the positive developments in their collaboration with AstraZeneca and the potential for milestone revenue recognition from their R&D pipeline. CICC, on the other hand, raised its target price to $12 and kept its rating at "Outperform," reflecting confidence in the company's earnings forecasts and innovative assets.
CICC
Outperform
Price Target
$11 -> $12
2026-02-02
maintain
The analyst rating for CSPC Pharma (01093.HK) is maintained at "Underperform" by BofAS due to sales pressure, despite the positive developments in their collaboration with AstraZeneca and the potential for milestone revenue recognition from their R&D pipeline. CICC, on the other hand, raised its target price to $12 and kept its rating at "Outperform," reflecting confidence in the company's earnings forecasts and innovative assets.
BofA Securities
Underperform
maintain
2026-02-02
Reason
The analyst rating for CSPC Pharma was reiterated at "Underperform" by BofA Securities despite the positive news regarding the agreement with AstraZeneca. The reasons for this rating include anticipated sales pressure on the company's existing product portfolio and the limited short-term contribution expected from the R&D pipeline, as most key assets are still in the early stages of development.
BofA Securities
Underperform
Price Target
2026-02-02
maintain
The analyst rating for CSPC Pharma was reiterated at "Underperform" by BofA Securities despite the positive news regarding the agreement with AstraZeneca. The reasons for this rating include anticipated sales pressure on the company's existing product portfolio and the limited short-term contribution expected from the R&D pipeline, as most key assets are still in the early stages of development.
Daiwa
Daiwa
Buy
to
Hold
downgrade
$100 -> $116
2026-01-05
Reason
The analyst rating from Daiwa reflects a more cautious approach for 2026, recommending a selective strategy focused on quality stocks after a strong performance in the Chinese biopharmaceutical sector in 2025. The downgrade of AKESO from Buy to Hold is attributed to a lack of short-term catalysts, despite an increase in its target price. Conversely, Daiwa has raised the target price for INNOVENT BIO, indicating confidence in its potential, while maintaining a Sell rating for CSPC PHARMA, suggesting a negative outlook for that stock.
Daiwa
Buy
to
Hold
Price Target
$100 -> $116
2026-01-05
downgrade
The analyst rating from Daiwa reflects a more cautious approach for 2026, recommending a selective strategy focused on quality stocks after a strong performance in the Chinese biopharmaceutical sector in 2025. The downgrade of AKESO from Buy to Hold is attributed to a lack of short-term catalysts, despite an increase in its target price. Conversely, Daiwa has raised the target price for INNOVENT BIO, indicating confidence in its potential, while maintaining a Sell rating for CSPC PHARMA, suggesting a negative outlook for that stock.
BofA Securities
BofA Securities
Buy
maintain
$45
2025-12-24
Reason
The analyst rating for HANSOH PHARMA was maintained at "Buy" due to the company achieving the highest year-over-year sales growth among its peers at 8.6% in October, with most of its key products recording double-digit month-over-month growth. In contrast, HENGRUI PHARMA received an "Underperform" rating because several of its key products faced pressure, despite a 2% year-over-year increase in total sample sales. SINO BIOPHARM was also rated "Buy" due to the significant licensing potential of its pipeline products, despite a reduction in sales forecasts for some products. CSPC PHARMA was rated "Underperform" due to sluggish sales performance in October.
BofA Securities
Buy
Price Target
$45
2025-12-24
maintain
The analyst rating for HANSOH PHARMA was maintained at "Buy" due to the company achieving the highest year-over-year sales growth among its peers at 8.6% in October, with most of its key products recording double-digit month-over-month growth. In contrast, HENGRUI PHARMA received an "Underperform" rating because several of its key products faced pressure, despite a 2% year-over-year increase in total sample sales. SINO BIOPHARM was also rated "Buy" due to the significant licensing potential of its pipeline products, despite a reduction in sales forecasts for some products. CSPC PHARMA was rated "Underperform" due to sluggish sales performance in October.
Morgan Stanley
Morgan Stanley
Overweight
downgrade
$11
2025-12-17
Reason
The analyst rating for CSPC PHARMA was updated to "Overweight" by Morgan Stanley due to a revision in the company's sales forecasts for 2025-26, which were cut by 1% and 2%, respectively. Despite these reductions, the 2027 sales forecast remained unchanged. Additionally, estimates for recurring net profit were lowered by 4% for 2025-26, while the 2027 estimate stayed the same. The target price was also decreased from HKD11 to HKD10.4, reflecting the adjustments made based on the company's 3Q25 results and management guidance.
Morgan Stanley
Overweight
Price Target
$11
2025-12-17
downgrade
The analyst rating for CSPC PHARMA was updated to "Overweight" by Morgan Stanley due to a revision in the company's sales forecasts for 2025-26, which were cut by 1% and 2%, respectively. Despite these reductions, the 2027 sales forecast remained unchanged. Additionally, estimates for recurring net profit were lowered by 4% for 2025-26, while the 2027 estimate stayed the same. The target price was also decreased from HKD11 to HKD10.4, reflecting the adjustments made based on the company's 3Q25 results and management guidance.
Valuation Metrics

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
13.95
Current PE
18.02
Overvalued PE
17.07
Undervalued PE
10.84

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.54
Current EV/EBITDA
10.46
Overvalued EV/EBITDA
10.85
Undervalued EV/EBITDA
6.23

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.34
Current PS
2.86
Overvalued PS
2.89
Undervalued PS
1.80

Financials

AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly
Buyback
Short Selling
People Also Watch
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia